More frequent in DLBCL is the upregulation of Myc protein expression, which has been identified in 25–30% of patients.1, 2 Increased Myc expression is correlated with poorer outcome in patients treated with standard of care therapies including rituximab and chemotherapy. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.